CAS President Dr Giuseppe Fuda's letter to Dr Cynthia K. Colapinto, Director, Policy and Data Division, Health Product Shortage Directorate at Health Canada, with a list of medications that should be considered for inclusion on the Critical and Vulnerable Drug List.
En savoir plus
CAS President Dr Giuseppe Fuda's letter to Dr Cynthia K. Colapinto, Director, Policy and Data Division, Health Product Shortage Directorate at Health Canada, with a list of medications that should be considered for inclusion on the Critical and Vulnerable Drug List.
En savoir plus
We have received reports from anesthesiologists in Ontario regarding coring issues when
using BD Blunt needles to draw medications. Coring involves a small piece of the rubber
stopper detaching during needle insertion, which may lead to contamination or injection of
rubber fragments into patients.
En savoir plus
On September 29, 2024, Baxter International (Baxter US) announced that its North Cove manufacturing facility in Marion, North Carolina, was damaged by flooding caused by Hurricane Helene.1 This U.S. facility mainly manufactures intravenous and peritoneal dialysis solutions. This facility was responsible for a significant proportion of the intravenous fluids supply in the United States.
En savoir plus
Chloroprocaine was withdrawn from the Canadian market in 2012 due to a corporate decision by its manufacturer, citing a shortage of essential raw materials needed for production. However, chloroprocaine remained in production and widely available in the United States and Europe.
En savoir plus
Chloroprocaine was discontinued from the Canadian market in 2012, as a result of a corporate decision made by its manufacturer (in the context of a shortage of raw materials required to produce it). Chloroprocaine is still manufactured and broadly available in the United States and Europe.
En savoir plus
CAS has become aware that some hospitals are experiencing a shortage of endotracheal tubes. Health Canada’s Equipment Shortages Unit has shared with CAS that this is a result of a combination of factors (including a product recall and global raw materials shortage).
En savoir plus
There are shortages affecting lidocaine and bupivacaine solutions that contain
epinephrine. Of note, the plain formats (without epinephrine) are readily available.
For lidocaine with epinephrine, there are three Canadian suppliers. Only two of the
three are currently experiencing supply chain issues:
En savoir plus
Canadian suppliers of succinylcholine chloride in Canada are currently reporting shortages due
to a combination of production interruptions and increased demand. It is expected that
hospitals will see reduced supplies of this medication in the coming weeks/months and the exact duration of this supply issue is unclear at this time.
En savoir plus
As you are likely aware, we are experiencing a shortage of Sandoz Ketamine Hydrochloride that will impact supplies across Canada. This shortage is due to a quality control concern that is currently under investigation. Because of this concern there is uncertainty as to when
production will resume.
En savoir plus
As you are likely aware, we are experiencing a shortage of Sandoz Ketamine Hydrochloride that will impact supplies across Canada. This shortage is due to a quality control concern that is currently under investigation. Because of this concern there is uncertainty as to when
production will resume.
En savoir plus
As you are likely aware, we are experiencing a shortage of Sandoz Ketamine Hydrochloride that will impact supplies across Canada. This shortage is due to a quality control concern that is currently under investigation. Because of this concern there is uncertainty as to when
production will resume.
En savoir plus
Response to letter send by CAS President Dr Douglas B DuVal regarding availability of local anesthetics in Canada.
En savoir plus
Letter from CAS President Dr Douglas B DuVal to Health Canada regarding the availability of local anesthetics in Canada.
En savoir plus